We are pleased to announce three new endorsements from national organizations: MS Australia, MS Ireland and MS Research Australia. The Société Francophone de la Sclérose En Plaques, representing French-speaking MS healthcare professionals, has also endorsed the report, in addition to 19 other organizations from around the world. In this month’s newsletter, we are reaching out to other national patient groups and professional societies and encouraging each one to use the report to bring about change.
Spread the word
If you have links with local professional or advocacy organizations that are not yet aware of the MS Brain Health report or have not signalled their support for the MS Brain Health recommendations, please bring the initiative to their attention. Could your local group include the evidence-based MS Brain Health materials in awareness-raising activities? For example, you may want to use chapter 2, ‘Speed up referral and diagnosis’, to encourage the general public to act promptly if early symptoms of MS develop. Let us know how we can best engage with your local group and work effectively together to bring about change.
To extend the reach of the MS Brain Health recommendations, we plan to translate our key resources into other languages. A French translation of the executive summary and recommendations is now available; please let us know which other languages you would like us to prioritize.
Please continue to spread the word that time matters in MS.
- Forward this newsletter: if you have friends or colleagues who might be interested in our activities, please encourage them to get involved.
- Follow us on Twitter @MSBrainHealth: find out about MS Brain Health news as it happens with our Twitter updates, and retweet to keep your followers up to date.
Thank you for being part of the MS Brain Health initiative!
Gavin Giovannoni, MD
Professor of Neurology and Chair of the MS Brain Health Steering Committee
On behalf of the MS Brain Health Steering Committee: Gavin Giovannoni, Peer Baneke, Helmut Butzkueven, Giancarlo Comi, Kathleen Costello, Jeremy Hobart, Gisela Kobelt and Christoph Thalheim
Preparation and publication of this newsletter was funded by a grant from AbbVie and by an educational grant from Novartis, both of whom had no influence on the content